BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 17076970)

  • 1. The onset of effect for escitalopram and its relevance for the clinical management of depression.
    Wade A; Friis Andersen H
    Curr Med Res Opin; 2006 Nov; 22(11):2101-10. PubMed ID: 17076970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of escitalopram on sleep problems in depressed patients.
    Lader M; Andersen HF; Baekdal T
    Hum Psychopharmacol; 2005 Jul; 20(5):349-54. PubMed ID: 15912558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
    Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
    Bech P; Lönn SL; Overø KF
    J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of escitalopram in patients with severe depression: a pooled analysis.
    Llorca PM; Azorin JM; Despiegel N; Verpillat P
    Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
    Bech P; Andersen HF; Wade A
    Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superiority of escitalopram to paroxetine in the treatment of depression.
    Kasper S; Baldwin DS; Larsson Lönn S; Boulenger JP
    Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of educational information on depressed outpatients treated with escitalopram: a semi-naturalistic study.
    Leinonen E; Niemi H
    Nord J Psychiatry; 2007; 61(2):109-14. PubMed ID: 17454725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life.
    Soares CN; Arsenio H; Joffe H; Bankier B; Cassano P; Petrillo LF; Cohen LS
    Menopause; 2006; 13(5):780-6. PubMed ID: 16894334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania.
    Sussman N; Mullen J; Paulsson B; Vågerö M
    J Affect Disord; 2007; 100 Suppl 1():S55-63. PubMed ID: 17383736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder.
    Pinto C; Trivedi JK; Vankar GK; Sharma PS; Narasimha V
    J Indian Med Assoc; 2007 Jul; 105(7):364, 366, 368 passim. PubMed ID: 18178988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escitalopram in the treatment of anxiety symptoms associated with depression.
    Bandelow B; Andersen HF; Dolberg OT
    Depress Anxiety; 2007; 24(1):53-61. PubMed ID: 16937393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
    Wade AG; Schlaepfer TE; Andersen HF; Kilts CD
    J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder.
    von Knorring AL; Olsson GI; Thomsen PH; Lemming OM; Hultén A
    J Clin Psychopharmacol; 2006 Jun; 26(3):311-5. PubMed ID: 16702897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder.
    Schmitt L; Tonnoir B; Arbus C
    Neuropsychobiology; 2006; 54(4):201-7. PubMed ID: 17337913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates of remission/euthymia with quetiapine monotherapy compared with placebo in patients with acute mania.
    Ketter TA; Jones M; Paulsson B
    J Affect Disord; 2007; 100 Suppl 1():S45-53. PubMed ID: 17383011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B; Moore N; Verdoux H; Auray JP
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Severe forms of depression: the efficacy of escitalopram].
    Spadone C
    Encephale; 2009 Apr; 35(2):152-9. PubMed ID: 19393384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.